...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International clinical psychopharmacology >Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine.
【24h】

Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine.

机译：齐拉西酮和奥氮平治疗的患者观察到的代谢作用比较。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study aimed to examine the impact of ziprasidone and olanzapine on QTc interval, weight and metabolic parameters in adults with schizophrenia and other psychoses. A retrospective cohort chart review was performed of 191 randomly selected patients who were being treated with ziprasidone or olanzapine in an integrated health care system. Significant differences on QTc interval were not observed. A significant weight gain was observed in olanzapine-treated patients (P<0.001) but not in the ziprasidone-treated cohort (P>0.05). Furthermore, adverse metabolic changes associated with olanzapine administration were significant with respect to effects on total cholesterol (P=0.01), triglycerides (P=0.05) and haemoglobin A1C (HbA1C) (P<0.05), whereas significant favourable metabolic effects were observed in ziprasidone-treated patients with regard to total cholesterol (P<0.05), low-density lipoprotein (LDL) (P<0.01), high-density lipoprotein (HDL) (P<0.05) and HbA1c (P<0.05). Our results suggest that these two atypical antipsychotics are safe and well tolerated from a cardiovascular standpoint, with no differences in QTc interval prolongation being observed. Olanzapine-treated patients exhibited significant weight increases, whereas ziprasidone-treated patients exhibited weight loss. Olanzapine treatment was also associated with significant adverse effect on patient's lipid profile and HbA1c. These adverse metabolic effects were not observed in ziprasidone-treated patients although favourable effects were observed with regard to effect on total cholesterol, LDL, HDL and HbA1c.
机译：这项研究旨在检查齐拉西酮和奥氮平对患有精神分裂症和其他精神病的成年人QTc间隔，体重和代谢参数的影响。回顾性队列研究回顾了191名随机接受综合治疗系统接受齐拉西酮或奥氮平治疗的患者。没有观察到QTc间隔的显着差异。在奥氮平治疗的患者中观察到显着的体重增加（P <0.001），但在齐拉西酮治疗的队列中未观察到体重增加（P> 0.05）。此外，与奥氮平相关的不良代谢变化在总胆固醇（P = 0.01），甘油三酸酯（P = 0.05）和血红蛋白A1C（HbA1C）的影响方面具有显着性（P <0.05），而在奥氮平中则观察到显着的有利代谢作用。齐拉西酮治疗的患者的总胆固醇（P <0.05），低密度脂蛋白（LDL）（P <0.01），高密度脂蛋白（HDL）（P <0.05）和HbA1c（P <0.05）。我们的结果表明，从心血管的观点来看，这两种非典型的抗精神病药是安全的，并且耐受性良好，没有观察到QTc间隔延长的差异。奥氮平治疗的患者体重显着增加，而齐拉西酮治疗的患者体重减轻。奥氮平治疗还对患者的血脂和HbA1c产生重大不良影响。在齐拉西酮治疗的患者中未观察到这些不良的代谢作用，尽管在总胆固醇，LDL，HDL和HbA1c的作用方面观察到了有利的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号